Lupin Pharmaceuticals
Lupin Pharmaceuticals, Inc. is the U.S. commercial subsidiary of Indian parent Lupin Ltd, commercializing generics, complex generics, inhalation, branded, and specialty medicines across 100+ countries via its proprietary PrecisionSphere™ injectable platform and traditional pharmaceutical distribution channels.
- Company typePrivate
- Founded1968
- HeadquartersBaltimore, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lupin Pharmaceuticals does
Lupin Pharmaceuticals, Inc. (LPI) is the U.S. commercial subsidiary of Lupin Ltd, the Indian multinational pharmaceutical company founded in 1968 by Dr. Desh Bandhu Gupta. Headquartered in Naples, Florida, LPI commercializes a diversified pharmaceutical portfolio spanning generics, complex generics, inhalation medications, branded products, and specialty medicines, serving healthcare providers and patients across 100+ countries. The company is a major pharmaceutical player by prescriptions in the U.S. and operates through country-specific brand entities in Canada, the UK, Germany, Australia, Brazil, Mexico, South Africa, the Philippines, Switzerland, and the Netherlands.
The company's underlying technology platform centers on advanced pharmaceutical manufacturing, including a proprietary long-acting injectable platform branded PrecisionSphere™, from which Lupin launched Risperidone Long-Acting Injectable with 180-day Competitive Generic Therapy exclusivity in the U.S. in November 2025. Additional capability is being built in peptide ingredient production and contract development and manufacturing services (CDMO) through an expansion of the Dabhasa, India facility, targeting the global advanced therapeutics and peptide market. The company also offers generics and complex generics across multiple therapeutic areas and an innovative medicines portfolio addressing unmet medical needs.
Lupin's revenue model is built on traditional pharmaceutical distribution: products move through wholesale distributors, pharmacy networks, healthcare institutions, and institutional buyers in the U.S. and global markets. Pricing is not publicly disclosed at the product level. Recent significant cash outflows include a $90 million settlement with Astellas over Mirabegron patent litigation and a $30 million antitrust settlement with Humana as part of the consolidated In Re Generic Pharmaceuticals Antitrust Litigation. Marketing channels are primarily LinkedIn and the corporate news/media section, with no public pricing or digital channel data disclosed.
Lupin Pharmaceuticals firmographics
Firmographics- Name
- Lupin Pharmaceuticals
- Legal name
- Lupin Pharmaceuticals, Inc.
- Website
- https://lupinpharmaceuticals.com
- Company type
- Private
- Founded year
- 1968
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Lupin Pharmaceuticals, Inc. is the U.S. commercial subsidiary of Indian parent Lupin Ltd, commercializing generics, complex generics, inhalation, branded, and specialty medicines across 100+ countries via its proprietary PrecisionSphere™ injectable platform and traditional pharmaceutical distribution channels.
- Ownership category
- akta.pro rank
Lupin Pharmaceuticals industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Lupin Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Baltimore
- HQ country
- United States
- HQ region
- North America
Markets served
Lupin Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure, Marketing or Sales
Distribution channels1 record
Marketing channels2 records
Lupin Pharmaceuticals product offering
Product offeringCore offering
Lupin Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and commercializes generic, complex generic, inhalation, branded, and specialty pharmaceutical products for the U.S. and international markets. The company also operates proprietary drug delivery platforms such as PrecisionSphere™ for long-acting injectables and provides contract development and manufacturing (CDMO) services for peptides and advanced therapeutics.
Product overview
Lupin Pharmaceuticals is a global pharmaceutical company offering a diversified portfolio of generic medicines, complex generics, innovative medicines, and specialty medications. The company operates its proprietary PrecisionSphere™ long-acting injectable platform for extended-release formulations. Product offerings include generics and complex generics targeting various therapeutic areas, innovative branded medications, and contract development manufacturing (CDMO) services for peptides and advanced therapeutics through its expanded Dabhasa facility in India.
Differentiator
Problem solved
Functional benefit
Products and services
- Risperidone Long-Acting Injectable A long-acting injectable formulation of risperidone, used in the treatment of psychiatric conditions such as schizophrenia and bipolar disorder, offered to U.S. healthcare providers and patients with 180-day competitive generic therapy exclusivity.
- Generics and Complex Generics Lupin's core portfolio of generic pharmaceutical products, including complex generics that provide cost-effective alternatives to brand-name medications across a broad range of therapeutic areas, targeting patients and healthcare providers globally.
- Innovative Medicines (Branded and Specialty) Specialty and branded pharmaceutical products focused on addressing unmet medical needs through novel therapeutic approaches, including inhalation medications, for healthcare providers and patients.
- Mirabegron Generic Generic version of Astellas' Myrbetriq (mirabegron), a medication used for the treatment of overactive bladder, offered as a cost-effective alternative to the brand-name product for U.S. patients and healthcare providers.
- Peptide CDMO Services Contract development and manufacturing services for peptides and advanced therapeutics, supported by Lupin's expanded Dabhasa facility in India with peptide ingredient production capacity, offered to pharmaceutical and biotechnology clients in the global peptide market.
Companies that use Lupin Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Lupin Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Lupin Pharmaceuticals partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
Lupin Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Teva Pharmaceutical Industries: Largest generic pharmaceutical manufacturer globally with a deep US generics portfolio. Directly comparable to Lupin in oral solids, complex generics, and specialty categories, with overlapping therapeutic areas.
- Sandoz (Novartis): Pure-play global generics and biosimilars leader spun out of Novartis. Directly competes with Lupin in US retail generics and complex generics, with similar customer bases (pharmacies, wholesalers, hospitals).
- Viatris: Major US-headquartered generics and specialty pharma company formed via Mylan-Upjohn merger. Direct competitor in generic and complex generics across the same channels as Lupin.
- Apotex: Canadian-based generic pharmaceutical manufacturer with significant US market presence. Directly comparable to Lupin in oral solid generics, complex generics, and injectable product lines.
- Aurobindo Pharma: India-based global generic pharmaceutical company with a substantial US subsidiary (Aurobindo Pharma USA). Closely comparable Indian-headquartered peer with overlapping US generics portfolio and similar scale.
- Sun Pharmaceutical Industries: India's largest pharmaceutical company and major US generics player via Sun Pharma Global FZE. Directly comparable Indian peer with similar specialty-generics mix and US distribution footprint.
- Dr. Reddy's Laboratories: Indian multinational generic and specialty pharmaceutical company with strong US operations. Directly comparable to Lupin in injectable generics, biosimilars, and branded specialty categories.
- Hikma Pharmaceuticals: Jordan-headquartered specialty and generic pharmaceutical company with major US operations (Hikma Pharmaceuticals USA). Comparable to Lupin in injectables, generics, and specialty branded products.
- Zydus Lifesciences: Indian multinational pharmaceutical company with US generics operations. Comparable Indian-headquartered peer with similar strategic focus on complex generics and specialty products in the US market.
Broad incumbents
- Endo International: US-focused specialty pharmaceutical company with generics and branded specialty franchises. Overlaps with Lupin's specialty generics portfolio and serves similar physician/payer customers in the US market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Lupin Pharmaceuticals social profiles
Digital presenceLupin Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lupin Pharmaceuticals leadership team
Management profileNumber of profiles
Lupin Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Lupin Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lupin Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lupin Pharmaceuticals
What does Lupin Pharmaceuticals do?
Lupin Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and commercializes generic, complex generic, inhalation, branded, and specialty pharmaceutical products for the U.S. and international markets. The company also operates proprietary drug delivery platforms such as PrecisionSphere™ for long-acting injectables and provides contract development and manufacturing (CDMO) services for peptides and advanced therapeutics.
Is Lupin Pharmaceuticals a public or private company?
Lupin Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was Lupin Pharmaceuticals founded?
Lupin Pharmaceuticals was founded in 1968. It employs 501 to 1,000 people.
Where is Lupin Pharmaceuticals based?
Lupin Pharmaceuticals is headquartered in Baltimore, United States, in the North America region.
Who are Lupin Pharmaceuticals's main competitors?
Direct peers on record are Teva Pharmaceutical Industries, Sandoz (Novartis), Viatris, Apotex, Aurobindo Pharma, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Hikma Pharmaceuticals and Zydus Lifesciences. Endo International is listed as a broad incumbent.
Does Lupin Pharmaceuticals have an API?
No public API is recorded for Lupin Pharmaceuticals.
What industry is Lupin Pharmaceuticals in?
Lupin Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.